Andrew Polson - Principal Scientist (Technology), Translational Oncology

Andrew Polson

Principal Scientist (Technology), Translational Oncology

Postdoc Mentor
Years at Genentech
Awards & Honors

I came to Genentech in 2002 after finishing my post-doctoral work in virology at UCSF. Since Joining Genentech I have been working on developing antibody-drug conjugates for the treatment of cancer. Learning the complex, team-oriented process of drug development has been fun and interesting. It has been very exciting to start projects that have the potential to help people and then see that potential start to become a reality.

Postdoctoral Mentor

It is a great pleasure be a post doc mentor at Genentech. Training the next generation of scientists makes me a better scientist and enriches my work. And Genentech provides a unique opportunity for the post doc to do basic science while interacting with people who work in both the basic science and translational fields. I think these interactions help provide a better perspective on their work and hopefully leads to their work having a greater impact.

Featured Publication

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.

Blood. 2017 Feb 2;129(5):609-618.

Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, Ellerman D, Gu C, Mathieu M, Dennis MS, Nguyen A, Zheng B, Zhang C, Lee G, Chu YW, Prell RA, Lin K, Laing ST, Polson AG./p>